- Home
- CIFR vs ACLX Comparison
CIFR vs ACLX Comparison
Compare CIFR & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$115.08
Company Overview
Basic Information| Metric | CIFR | ACLX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.7B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CIFR | ACLX |
|---|---|---|
| Price | $17.12 | $115.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | $24.91 | ★ $118.17 |
| AVG Volume (30 Days) | ★ 21.6M | 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $12.29 | $342.39 |
| Revenue Next Year | $240.53 | $170.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.88 | $47.86 |
| 52 Week High | $25.52 | $115.14 |
Technical Indicators
Market Signals| Indicator | CIFR | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 79.86 |
| Support Level | $12.53 | $63.46 |
| Resistance Level | $17.26 | N/A |
| Average True Range (ATR) | 1.37 | 0.11 |
| MACD | -0.17 | -0.62 |
| Stochastic Oscillator | 17.82 | 84.28 |
Price Performance
Historical Comparison CIFR
ACLX
About CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.